Lisata Therapeutics (CALADRIUS BIOSCIENCES)

Company Snapshot

Founded: 1980

Entity Type: Public

Employees: 26

Region: U.S.

Revenue: $1.0 Millions

Revenue Year: 2024

Headquarter: New Jersey, U.S.

Key Geographics: North America, Europe, Asia-Pacific

Corporate Address: 110 Allen Road, 2nd Floor Basking Ridge, New Jersey 07920 U.S. Tel. +1-908-842-0100 www.lisata.com

Company Overview

Lisata Therapeutics is a clinical-stage pharmaceutical company that develops innovative therapies for advanced solid tumors and other major diseases. Formed through the merger of Caladrius Biosciences and Cend Therapeutics, Lisata combines the expertise and resources of both companies to accelerate progress in targeted oncology treatments.

Lisata Therapeutics’ primary investigational product candidate, certepetide, aims to alter the tumor microenvironment by triggering a unique uptake pathway, facilitating improved penetration of anti-cancer medications into solid tumors. Certepetide activates a targeted transport mechanism within tumors, enabling more efficient delivery and accumulation of systemically administered anti-cancer drugs within the tumor site while sparing normal tissues from adverse effects.

Financial Highlights (FY 2024)

Net Revenue: ***

Total Current Liabilities: ***

Total Current Assets: ***

R&D expenses: ***

Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Lisata Therapeutics (CALADRIUS BIOSCIENCES) In Reports

Cell Therapy Biomanufacturing: Global Markets

BCC Research Market Analyst says global market for cell therapy biomanufacturing is expected to grow from $9.7 billion in 2024 and is projected to reach $16.7 billion by the end of 2029 at a CAGR of 11.5%.

Next-Generation Cancer Diagnostics: Technologies and Global Markets

BCC Research Market Report says next-generation cancer diagnostics market reached $8.7 billion in 2022 and should reach $15 billion by 2027, with a CAGR of 11.5%.

Global Market for Stem Cells

BCC Research Market Analysis Report says Stem Cells market has reached $32.1 billion in 2022 and should reach $65.6 billion by 2027 with a CAGR of 15.3%.

View All Reports

Lisata Therapeutics (CALADRIUS BIOSCIENCES) In News

CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug - Fierce Biotech

Fierce Biotech - Oct 09, 2025

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics - GlobeNewswire

GlobeNewswire - Sep 15, 2022

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics - Yahoo Finance

Yahoo Finance - Sep 14, 2022

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics - citybiz

citybiz - Sep 14, 2022

Read All News

Company's Business Segments

Therapies : The company offers therapies, specifically targeting advanced solid tumors and other major diseases, with a focus on innovative treatments and improved patient outcomes.

Applications/End User Industries

Oncology
Drug Discovery
Cancer Research

Research and Development
Cardiovascular and Autoimmune Diseases (Legacy Pipeline)

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment